{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T23:44:26Z","timestamp":1788479066393,"version":"build-2803163510"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.jpba.2018.07.040","type":"journal-article","created":{"date-parts":[[2018,7,25]],"date-time":"2018-07-25T23:59:32Z","timestamp":1532563172000},"page":"112-116","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Identification and structure elucidation of a new degradation impurity in the multi-component tablets of amlodipine besylate"],"prefix":"10.1016","volume":"162","author":[{"given":"Petr","family":"Gibala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9188-6585","authenticated-orcid":false,"given":"Michal","family":"Dou\u0161a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aneta","family":"Kalu\u017e\u00edkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcela","family":"Tkadlecov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"\u0160tefko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislav","family":"Kal\u00e1\u0161ek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji\u0159\u00ed","family":"B\u0159ich\u00e1\u010d","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2018.07.040_bib0005","doi-asserted-by":"crossref","first-page":"478","DOI":"10.2165\/00003495-199141030-00009","article-title":"Amlodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease","volume":"41","author":"Murdoch","year":"1991","journal-title":"Drugs"},{"key":"10.1016\/j.jpba.2018.07.040_bib0010","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.jpba.2005.10.029","article-title":"Identification and characterization of potential impurities of amlodipine maleate","volume":"40","author":"Sudhakar","year":"2006","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2018.07.040_bib0015","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1002\/rcm.2490","article-title":"A qualitative study of amlodipine and its related compounds by electrospray ionization tandem mass spectrometry","volume":"20","author":"Gibbons","year":"2006","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"10.1016\/j.jpba.2018.07.040_bib0020","first-page":"443","article-title":"Separation, identification and structural elucidation of a new impurity in the drug substance of smlodipine maleate using LC-MS\/MS, NMR and IR","volume":"83","author":"Reddy","year":"2010","journal-title":"Croat. Chem. Acta"},{"key":"10.1016\/j.jpba.2018.07.040_bib0025","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2298\/CICEQ121226011S","article-title":"Investigation of forced and total degradation products of amlodipine besylate by liquid chromatography and liquid chromatography-mass spectrometry","volume":"20","author":"Stoiljkovi\u0107","year":"2014","journal-title":"Chem. Ind. Chem. Eng. Q."},{"key":"10.1016\/j.jpba.2018.07.040_bib0030","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/B978-0-12-397220-0.00002-7","article-title":"Amlodipine besylate","volume":"37","author":"Ananchenko","year":"2012","journal-title":"Profiles Drug Subst. Excip. Relat. Methodol."},{"key":"10.1016\/j.jpba.2018.07.040_bib0035","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/mrc.2022","article-title":"Structure elucidation of thermal degradation products of amlodipine","volume":"45","author":"Devi","year":"2007","journal-title":"Magn. Reson. Chem."},{"key":"10.1016\/j.jpba.2018.07.040_bib0040","first-page":"375","article-title":"Stability of amlodipine besylate in two liquid dosage forms","volume":"39","author":"Nahata","year":"1999","journal-title":"J. Am. Pharm. Assoc."},{"key":"10.1016\/j.jpba.2018.07.040_bib0045","unstructured":"C.H. Ramesh, K.B.S. Rao, G.V.R. Tagore, M.S.S. Rao, Stable Pharmaceutical Formulation Composition Containing Amlodipine Besylate and Atenolol, US Patent WO 9,918,957, April 22, 1999."},{"key":"10.1016\/j.jpba.2018.07.040_bib0050","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1081\/PDT-120027414","article-title":"Amlodipine besylate\u2013excipients interaction in solid dosage form","volume":"9","author":"Abdoh","year":"2004","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.jpba.2018.07.040_bib0055","unstructured":"ICH Q1A (R2) Stability Testing of New Drug Substances and Products, Current Step 4 version, 6 February 2003."},{"key":"10.1016\/j.jpba.2018.07.040_bib0060","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1081\/PDT-120030249","article-title":"Influence of formaldehyde impurity in Polysorbate 80 and PEG 300 on the stability of a parenteral formulation of BMS-204352: identification and control of the degradation product","volume":"9","author":"Nassar","year":"2004","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.jpba.2018.07.040_bib0065","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1080\/10837450802244918","article-title":"Identification and control of a degradation product in Avapro film-coated tablet: low dose formulation","volume":"13","author":"Wang","year":"2008","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.jpba.2018.07.040_bib0070","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1023\/A:1016024923002","article-title":"Characterization of a solid state reaction product from a lyophilized formulation of a cyclic heptapeptide. A novel example of an excipient-induced oxidation","volume":"13","author":"Dubost","year":"1996","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jpba.2018.07.040_bib0075","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/jps.2600830702","article-title":"Crosslinking of gelatin capsules and its relevance to their in vitro-in vivo performance","volume":"83","author":"Dideni","year":"1994","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jpba.2018.07.040_bib0080","first-page":"21","article-title":"Purity of excipients","volume":"103","author":"J\u00e4kel","year":"2000","journal-title":"Excip. Toxic. Saf."},{"key":"10.1016\/j.jpba.2018.07.040_bib0085","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1002\/jps.23072","article-title":"The formation of furfural compounds in selected saccharide- and polysaccharide-based pharmaceutical excipients","volume":"101","author":"Dou\u0161a","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jpba.2018.07.040_bib0090","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/bdd.282","article-title":"Amlodipine bioequivalence study: quantification by liquid chromatography coupled to tandem mass spectrometry","volume":"22","author":"Carvalho","year":"2001","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.jpba.2018.07.040_bib0095","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/(SICI)1096-9888(199608)31:8<879::AID-JMS373>3.0.CO;2-F","article-title":"Quantitative determination of amlodipine in serum by liquid chromatography with atmospheric pressure chemical ionization tandem mass spectrometry","volume":"31","author":"Yasuda","year":"1996","journal-title":"J. Mass Spectrom."},{"key":"10.1016\/j.jpba.2018.07.040_bib0100","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jpha.2014.07.005","article-title":"LC, MSn and LC\u2013MS\/MS studies for the characterization of degradation products of amlodipine","volume":"5","author":"Tiwari","year":"2015","journal-title":"J. Pharm. Anal."},{"key":"10.1016\/j.jpba.2018.07.040_bib0105","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1365-2621.1968.tb01371.x","article-title":"Volatile compounds from heated glucose","volume":"33","author":"Walter","year":"1968","journal-title":"J. Food Sci."},{"key":"10.1016\/j.jpba.2018.07.040_bib0110","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1745-4549.1990.tb00126.x","article-title":"Relative reactivities of sugars in the formation of 5-hydroxymethylfurfural in sugar-catalyst model systems","volume":"14","author":"Hyoung","year":"1990","journal-title":"J. Food Process. Preserv."},{"key":"10.1016\/j.jpba.2018.07.040_bib0115","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1016\/j.xphs.2016.04.016","article-title":"Use of activated carbon in packaging to attenuate formaldehyde-induced and formic acid-induced degradation and reduce gelatin cross-linking in solid dosage forms","volume":"105","author":"Colgan","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jpba.2018.07.040_bib0120","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1248\/cpb.57.1096","article-title":"Generation of formaldehyde by pharmaceutical excipients and its absorption by meglumine","volume":"57","author":"Fujita","year":"2009","journal-title":"Chem. Pharm. Bull."},{"key":"10.1016\/j.jpba.2018.07.040_bib0125","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1248\/cpb.45.1814","article-title":"Fluorimetric determination of 1,2,3,4-tetrahydro isoquinolines in Biological materials by HPLC","volume":"45","author":"Shirahata","year":"1997","journal-title":"Chem. Pharm. Bull."},{"key":"10.1016\/j.jpba.2018.07.040_bib0130","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1023\/A:1016431422441","article-title":"Phenolic cyclization of epinephrine, metaproterenol, metaraminol, phenylephrine, and terbutaline with formaldehyde","volume":"4","author":"Chafetz","year":"1987","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jpba.2018.07.040_bib0135","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1021\/ac0490550","article-title":"Major degradation product identified in several pharmaceutical formulations against the common cold","volume":"77","author":"Marin","year":"2005","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jpba.2018.07.040_bib0140","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1271\/bbb.70129","article-title":"Browning of furfural and amino acids, and a novel compound, furpipate, formed from lysine and furfural","volume":"71","author":"Murata","year":"2007","journal-title":"Biosci. Biotechnol. Biochem."},{"key":"10.1016\/j.jpba.2018.07.040_bib0145","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.jpba.2011.03.027","article-title":"Drug-excipient compatibility testing-Identification and characterization of degradation products of phenylephrine in several pharmaceutical formulations against the common cold","volume":"55","author":"Dou\u0161a","year":"2011","journal-title":"J. Pharm. Biomed. Anal."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708518314729?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708518314729?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,10]],"date-time":"2018-12-10T02:06:05Z","timestamp":1544407565000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708518314729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":29,"alternative-id":["S0731708518314729"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2018.07.040","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification and structure elucidation of a new degradation impurity in the multi-component tablets of amlodipine besylate","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2018.07.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}